Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nanoform Finland

0.42 EUR

-2.55 %

3,703 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

-2.55 %
-43.32 %
-64.16 %
-64.16 %
-67.19 %
-65.12 %
-73.58 %
-93.96 %
-91.68 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
35.98M EUR
Turnover
213.34K EUR
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.4.
2026

General meeting '26

19.5.
2026

Interim report Q1'26

20.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Management buying, as they should at this price, if they have faith in the product. Market cap only €37 million, even though no catastrophic news has emerged and things are moving forward despite small setbacks. MFN – 2 Apr 26 Nanoform Finland Plc – Manager’s Transactions – Albert...
13 hours ago
by Tikanheitto
11
Nanoform small is powerful Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen - Nanoform small is... Nanoform Finland Oyj:n (”Yhtiö”) (Y-tunnus: 2730572-8) osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen,… The Board is also participating in the collective effort “...
3/20/2026, 9:32 AM
by Latupuikko
10
I would be very surprised if management hadn’t already considered an alternative in case the marketing authorization application for nanoenzalutamide gets stuck on that bioequivalence issue and the Cmax differences. One possible alternative to those more expensive non-inferiority...
10 hours ago
by jerej
7
Yes, that’s how I understand it too. It goes by the definitions of bioequivalence, where all of those should be within the reference values. The peculiar thing is that the higher peak must match the reference, even though there’s probably no biological difference if both fed and ...
3/31/2026, 6:58 AM
by jerej
7
Well, this kind of contraption is now what we’re facing. Will it now get hung up because of that Cmax? I dug up some enzalutamide food effect data from here. Here, Cmax decreases between fasted and fed states to below the 0.80-1.25 range. Additionally, a quote from the article, with...
3/30/2026, 11:07 PM
by jerej
7
Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026 Following the meeting, the authority acknowledged the strong scientific rationale ...
3/30/2026, 6:19 PM
by Kulkuri
6
Was this already known? Oh dear, a screw-up if it was. If a generic route is not available, things get much more difficult. A full application requires much larger studies… The partner may withdraw from the project now if the nanoformulation’s value add is not attractive enough to...
3/30/2026, 8:28 PM
by Clark kent
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.